Literature DB >> 34554185

Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis.

Giulio Disanto1, Rosaria Sacco1, Enos Bernasconi2,3,4, Gladys Martinetti5, Franco Keller5, Claudio Gobbi1,3, Chiara Zecca1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34554185      PMCID： PMC8461551          DOI： 10.1001/jamaneurol.2021.3609

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   29.907


× No keyword cloud information.
  32 in total

1.  Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2022-05-12       Impact factor: 4.330

2.  COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.

Authors:  Dejan Jakimovski; Karen Zakalik; Samreen Awan; Katelyn S Kavak; Penny Pennington; David Hojnacki; Channa Kolb; Alexis A Lizarraga; Svetlana P Eckert; Rosila Sarrosa; Kamath Vineetha; Keith Edwards; Bianca Weinstock-Guttman
Journal:  Vaccines (Basel)       Date:  2022-04-28

Review 3.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez
Journal:  J Neurol       Date:  2022-07-05       Impact factor: 6.682

4.  An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.

Authors:  Arkady Ovchinnikov; Oliver Findling
Journal:  Wien Med Wochenschr       Date:  2022-06-20

5.  Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.

Authors:  Asya I Wallach; Matthew Schiebel; Mary Ann Picone
Journal:  Mult Scler Relat Disord       Date:  2022-05-06       Impact factor: 4.808

6.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

Review 7.  Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis.

Authors:  Manila Hada; Andrew D Mosholder; Kira Leishear; Silvia Perez-Vilar
Journal:  Neurol Sci       Date:  2022-01-10       Impact factor: 3.830

8.  Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.

Authors:  Lutz Achtnichts; Barbara Jakopp; Michael Oberle; Krassen Nedeltchev; Christoph Andreas Fux; Johann Sellner; Oliver Findling
Journal:  Vaccines (Basel)       Date:  2021-12-11

Review 9.  Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions.

Authors:  Michael J Peluso; Joanna Donatelli; Timothy J Henrich
Journal:  Transl Res       Date:  2021-11-12       Impact factor: 7.012

10.  Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.

Authors:  Hamza Mahmood Bajwa; Frederik Novak; Anna Christine Nilsson; Christian Nielsen; Dorte K Holm; Kamilla Østergaard; Agnes Hauschultz Witt; Keld-Erik Byg; Isik S Johansen; Kristen Mittl; William Rowles; Scott S Zamvil; Riley Bove; Joseph J Sabatino; Tobias Sejbaek
Journal:  Mult Scler Relat Disord       Date:  2022-03-06       Impact factor: 4.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.